NCT05751603

Brief Summary

After surgery is completed under general anesthesia, extubation is performed after recovery from anesthesia, and during this process, bucking, coughing, and rapid and excessive hemodynamic fluctuations occur very often. These phenomena can lead to high intrathoracic pressure, venous congestion, hematoma formation, or increased bleeding after major neck surgery. (1) They can also increase the risk of aerosol generation, which can transmit infection to health care workers. (2) For this, smooth extubation is required. Methods of administering drugs such as lidocaine, opioids, or dexmedetomidine have been proposed for smooth extubation. (3-5) As a disadvantage, the use of these drugs may be associated with deep sedation and reduced airway reflexes . Recently, Babu et al. (6) reported that bucking and coughing during extubation could be reduced by changing the timing of administering a muscle relaxant antagonist rather than using these sedative drugs, and thus complications related to extubation could be reduced. In general, in the awakening process, it was common to administer the muscle relaxant at the point of recovery of spontaneous breathing. However, Babu et al. demonstrated the possibility of safe and smooth extubation by changing the timing of administering neostigmine without the use of sedatives or narcotic analgesics, but there are few studies on sugammadex. Therefore, when recovering from general anesthesia, sugammadex was administered before and immediately after extubation to evaluate and compare smooth extubation (ie, comparison of the frequency of bucking and coughing).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 21, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 2, 2023

Completed
1.6 years until next milestone

Study Start

First participant enrolled

October 3, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 3, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 3, 2025

Completed
Last Updated

July 25, 2024

Status Verified

July 1, 2024

Enrollment Period

1 year

First QC Date

February 21, 2023

Last Update Submit

July 23, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • extubation quality score

    score based on the incidence and severity of coughing straining

    immediate after extubation

Secondary Outcomes (3)

  • time to respiration

    immediate after extubation

  • time to extubation

    immediate after extubation

  • sore throat in postanesthetic care unit

    in postanesthetic care unit

Study Arms (2)

Control group

NO INTERVENTION

Routine anesthetic process; sugammadex is administered when spontaneous respiration is returned (before extubation)

Experimental group

EXPERIMENTAL

sugammadex is administered just after extubation.

Drug: sugammadex

Interventions

sugammadex is administered just after extubation

Experimental group

Eligibility Criteria

Age19 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patients undergoing general anesthesia for thyroid surgery.
  • aged between 19 and 64 years
  • American Society of Anesthesiologists physical status I and II

You may not qualify if:

  • patients with malformation or tumor of the upper respiratory tract
  • patients with risk of aspiration
  • obese cases with a BMI \> 35
  • patients in which tracheal intubation was difficult
  • refusal to participate in research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Sugammadex

Intervention Hierarchy (Ancestors)

gamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsPolycyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydrates

Central Study Contacts

yun jeong chae, Ph D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

February 21, 2023

First Posted

March 2, 2023

Study Start

October 3, 2024

Primary Completion

October 3, 2025

Study Completion

October 3, 2025

Last Updated

July 25, 2024

Record last verified: 2024-07